BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23233599)

  • 1. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?
    Hutchings M
    Hematology Am Soc Hematol Educ Program; 2012; 2012():322-7. PubMed ID: 23233599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
    Hutchings M
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma.
    Crocchiolo R; Fallanca F; Giovacchini G; Ferreri AJ; Assanelli A; Verona C; Pescarollo A; Bregni M; Ponzoni M; Gianolli L; Fazio F; Ciceri F
    Ann Hematol; 2009 Dec; 88(12):1229-36. PubMed ID: 19468730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
    Evens AM; Kostakoglu L
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):135-43. PubMed ID: 25696846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of PET in lymphoma.
    Gallamini A; Borra A
    Curr Treat Options Oncol; 2014 Jun; 15(2):248-61. PubMed ID: 24619427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.
    Goldschmidt N; Or O; Klein M; Savitsky B; Paltiel O
    Ann Hematol; 2011 Feb; 90(2):165-71. PubMed ID: 20706721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
    Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
    Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
    Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
    Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.
    Hutchings M; Loft A; Hansen M; Berthelsen AK; Specht L
    Eur J Haematol; 2007 Mar; 78(3):206-12. PubMed ID: 17253974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography.
    Hutchings M
    Cancer J; 2018; 24(5):215-222. PubMed ID: 30247256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?
    Kostakoglu L; Gallamini A
    J Nucl Med; 2013 Jul; 54(7):1082-93. PubMed ID: 23818548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
    Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
    Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
    Kostakoglu L; Evens AM
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma.
    Robertson VL; Anderson CS; Keller FG; Halkar R; Goodman M; Marcus RB; Esiashvili N
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):324-32. PubMed ID: 20646867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases.
    Molin D; Hagberg H; Suurküla M; Aström G
    Acta Oncol; 2010 May; 49(4):526-8. PubMed ID: 20397779
    [No Abstract]   [Full Text] [Related]  

  • 18. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
    El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
    J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET/CT for therapy response assessment in lymphoma.
    Hutchings M; Barrington SF
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.